Document is current

Article History

Received: 20 July 2021

Accepted: 29 August 2022

First Online: 19 September 2022

Declarations

:

: This study was approved by the Ethics Committee of the National Center of Neurology and Psychiatry, Japan and the ethics committees of the participating medical facilities. All methods were performed in accordance with relevant guidelines and regulations. Additionally, informed consent was obtained from all participants.

: Not applicable.

: Dr. Okajima has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai Co., Ltd., and Takeda Pharmaceuticals for projects unrelated to the submitted work. Dr. Inada has received speaker’s honoraria and manuscript fees from Astellas Pharma Inc., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Dr. Yamadera has received research support from Eisai Co., Ltd. Dr. Kamei has received speaker’s honoraria from Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Dr. Inoue has received research funding from MSD K.K. and speaker’s honoraria from Eisai Co., Ltd., MSD K.K., and Takeda Pharmaceutical Co., Ltd. He has also received other financial or non-financial interests from Eisai Co., Ltd. The other authors have no conflicts of interest to declare.